Hepatocellular carcinoma - United States, 2001-2006
- PMID: 20448528
Hepatocellular carcinoma - United States, 2001-2006
Abstract
Liver cancer, primarily hepatocellular carcinoma (HCC), is the third leading cause of death from cancer worldwide and the ninth leading cause of cancer deaths in the United States. Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for an estimated 78% of global HCC cases. To determine trends in HCC incidence in the United States, CDC analyzed data for the period 2001-2006 (the most recent data available) from CDC's National Program of Cancer Registries (NPCR) and the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) surveillance system. This report summarizes the results of that analysis, which determined that the average annual incidence rate of HCC for 2001-2006 was 3.0 per 100,000 persons and increased significantly from 2.7 per 100,000 persons in 2001 to 3.2 in 2006, with an average annual percentage change in incidence rate (APC) of 3.5%. The largest increases in HCC incidence rates were among whites (APC = 3.8), blacks (APC = 4.8), and persons aged 50-59 years (APC = 9.1). Among states, HCC incidence rates varied widely, ranging from 1.4 per 100,000 in South Dakota to 5.5 in Hawaii. The results demonstrate a continuation of long-term increases in HCC incidence and persistent HCC racial/ethnic disparities. Development of viral hepatitis services, including screening with care referral for persons chronically infected with HBV or HCV, full implementation of vaccine-based strategies to eliminate hepatitis B, and improved public health surveillance are needed to help reverse the trend in HCC.
Similar articles
-
Surveillance for acute viral hepatitis - United States, 2007.MMWR Surveill Summ. 2009 May 22;58(3):1-27. MMWR Surveill Summ. 2009. PMID: 19478727
-
Hepatocellular carcinoma and hepatitis C in the United States.Hepatology. 2002 Nov;36(5 Suppl 1):S74-83. doi: 10.1053/jhep.2002.36807. Hepatology. 2002. PMID: 12407579 Review.
-
Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.Cancer. 1999 May 15;85(10):2132-7. Cancer. 1999. PMID: 10326690
-
Hepatocellular carcinoma incidence in Florida. Ethnic and racial distribution.Cancer. 2001 Mar 1;91(5):1046-51. Cancer. 2001. PMID: 11251958
-
Chronic hepatitis B and hepatocellular carcinoma.Clin Liver Dis. 2010 Aug;14(3):461-76. doi: 10.1016/j.cld.2010.05.009. Clin Liver Dis. 2010. PMID: 20638025 Review.
Cited by
-
The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation.Oncogene. 2016 Mar 10;35(10):1314-23. doi: 10.1038/onc.2015.190. Epub 2015 Jun 1. Oncogene. 2016. PMID: 26028023 Free PMC article.
-
Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide.Hepat Mon. 2012 Oct;12(10 HCC):e6894. doi: 10.5812/hepatmon.6894. Epub 2012 Oct 24. Hepat Mon. 2012. PMID: 23233864 Free PMC article.
-
Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.World J Hepatol. 2015 Jul 8;7(13):1742-54. doi: 10.4254/wjh.v7.i13.1742. World J Hepatol. 2015. PMID: 26167247 Free PMC article. Review.
-
Implantable arterial port-related bloodstream infection in patients with primary or metastatic hepatic malignancies.Am J Infect Control. 2013 Oct;41(10):930-2. doi: 10.1016/j.ajic.2013.01.018. Epub 2013 Apr 14. Am J Infect Control. 2013. PMID: 23594477 Free PMC article.
-
Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008.Mayo Clin Proc. 2012 Jan;87(1):9-16. doi: 10.1016/j.mayocp.2011.07.001. Mayo Clin Proc. 2012. PMID: 22212963 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical